Effects of carvedilol early after myocardial infarction: Analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN)

American Heart Journal

Volumn 154, Issue 4, 2007, Pages 637-644

  Fonarow, Gregg C ^a   Lukas, Mary Ann ^b   Robertson, Michele ^c   Colucci, Wilson S ^d   Dargie, Henry J ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARVEDILOL; PLACEBO;

ACUTE HEART INFARCTION; ARTICLE; BRADYCARDIA; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HEART ARREST; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CARBAZOLES; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPANOLAMINES; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK ASSESSMENT; SURVIVAL ANALYSIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34548731423     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.06.002     Document Type: Article

References (21)

1. Rasamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics---2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e71
2. Kober L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333 (1995) 1670-1676
3. Cleland J.G., Torabi A., and Khan N.K. Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction. Heart 91 Suppl 2 (2005) ii7-ii13
4. Velazquez E.J., Francis G.S., Armstrong P.W., et al. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. Eur Heart J 25 (2004) 1911-1919
5. Solomon S.D., Zelenkofske S., McMurray J.J., et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352 (2005) 2581-2588
6. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390
7. Pitt B., White H., Nicolau J., et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46 (2005) 425-431
8. Sackner-Bernstein J.D. New evidence from the CAPRICORN trial: the role of carvedilol in high-risk, post-myocardial infarction patients. Rev Cardiovasc Med 4 Suppl 3 (2003) S25-S29
9. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Circulation 110 (2004) 588-636
10. Wu A.H., Parsons L., Every N.R., et al. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction. J Am Coll Cardiol 40 (2002) 1389-1394
11. Spencer F.A., Meyer T.E., Gore J.M., et al. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure. Circulation 105 (2002) 2605-2610
12. Freemantle N., Cleland J., Young P., et al. Beta-blockade after myocardial infarction: systematic review and meta-regression analysis. BMJ 318 (1999) 1730-1737
13. ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 2 (1986) 57-66
14. MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J 6 (1985) 199-226
15. Hjalmarson A., Herlitz J., Holmberg S., et al. The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 67 (1983) I26-I32
16. Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Eur Heart J 8 (1987) 1056-1064
17. COMMIT Collaborative Group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1622-1632
18. Sabatine M.S. Something old, something new: beta blockers and clopidogrel in acute myocardial infarction. Lancet 366 (2005) 1587-1589
19. Fonarow G.C. Practical considerations of beta-blockade in the management of the post-myocardial infarction patient. Am Heart J 149 (2005) 984-993
20. Krum H., Roecker E.B., Mohacsi P., et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 289 (2003) 712-718
21. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321